CDR-3

N/A

Report date: 2026/03/19 16:59:31

Base Information

Drug NameCDR-3
Drug Alias Nameanti-CD3 trispecific LocATE antibody-dual antigen therapy (CDR-Life)anti-CD3 trispecific T-cell engager (CDR-Life)CDR-3
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Trispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionT cell surface glycoprotein CD3 modulators
TargetsT cell surface glycoprotein CD3
Therapy Area/IndicationsUrinary Bladder NeoplasmsCarcinoma, Non-Small-Cell LungCarcinoma, Squamous Cell +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySwitzerland
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesCDR-Life Inc
China Registration ClassN/A

Develop Information

Active CompaniesCDR-Life Inc
Inactive CompaniesN/A
Active IndicationsUrinary Bladder NeoplasmsCarcinoma, Non-Small-Cell LungCarcinoma, Squamous Cell +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A